Oxbow Advisors LLC Buys 24,668 Shares of Zoetis Inc. $ZTS

Oxbow Advisors LLC lifted its stake in Zoetis Inc. (NYSE:ZTS) by 85.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 53,469 shares of the company’s stock after buying an additional 24,668 shares during the period. Zoetis comprises 0.7% of Oxbow Advisors LLC’s portfolio, making the stock its 29th biggest holding. Oxbow Advisors LLC’s holdings in Zoetis were worth $7,824,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Halbert Hargrove Global Advisors LLC grew its holdings in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares in the last quarter. REAP Financial Group LLC lifted its position in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after purchasing an additional 131 shares during the period. NewSquare Capital LLC boosted its stake in Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after buying an additional 85 shares in the last quarter. ORG Partners LLC increased its holdings in Zoetis by 56.8% in the 2nd quarter. ORG Partners LLC now owns 232 shares of the company’s stock valued at $37,000 after buying an additional 84 shares during the period. Finally, Financial Consulate Inc. acquired a new position in shares of Zoetis in the 3rd quarter valued at $39,000. 92.80% of the stock is currently owned by institutional investors.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Analyst/market commentary argues Zoetis is undervalued and oversold after the pullback, highlighting attractive valuation and dividend/earnings durability as a buying opportunity. Zoetis: Undervalued And Oversold
• Positive Sentiment: Wall Street Zen upgraded Zoetis to a “Buy,” adding near‑term positive analyst pressure and supporting the idea that the recent pullback creates opportunity. Zoetis (NYSE:ZTS) Upgraded by Wall Street Zen to “Buy” Rating
• Positive Sentiment: Zacks highlights Zoetis’ history of earnings surprises and says the company has the indicators that point toward another potential beat, which could support the stock on next results. Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Yahoo Finance frames the 24% one‑year pullback as a potential buying opportunity for investors focused on long‑term fundamentals and valuation. Is Zoetis (ZTS) Offering An Opportunity After A 24% One-Year Share Price Pullback
• Neutral Sentiment: Aggregated analyst consensus remains cautious — the average recommendation is “Hold,” indicating mixed views despite some buy calls. Zoetis Inc. (NYSE:ZTS) Given Average Recommendation of “Hold” by Analysts
• Neutral Sentiment: A Benzinga roundup of eight analyst ratings shows varied opinions and target prices, underscoring the lack of consensus that’s keeping trading choppy. 7ZTS : What 8 Analyst Ratings Have To Say About Zoetis
• Negative Sentiment: Piper Sandler downgraded Zoetis from “Overweight” to “Neutral” and cut its price target sharply to $135 from $190 — a high‑profile downgrade that likely pressured sentiment and contributed to the stock decline. Piper Sandler Downgrades Zoetis Inc. (ZTS) to Neutral

Analysts Set New Price Targets

A number of research analysts have commented on ZTS shares. Weiss Ratings upgraded shares of Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 13th. Barclays began coverage on Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 target price for the company. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a research report on Friday. JPMorgan Chase & Co. dropped their price objective on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Finally, KeyCorp initiated coverage on shares of Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating on the stock. Five research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $152.91.

Zoetis Price Performance

Shares of NYSE:ZTS traded down $0.36 during midday trading on Friday, reaching $124.04. The company’s stock had a trading volume of 3,339,607 shares, compared to its average volume of 3,978,461. The business’s fifty day simple moving average is $123.58 and its 200-day simple moving average is $138.43. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.40. The company has a market capitalization of $54.66 billion, a P/E ratio of 20.88, a P/E/G ratio of 2.16 and a beta of 0.97.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.08. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm’s quarterly revenue was up .5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be issued a $0.53 dividend. This is an increase from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis’s dividend payout ratio (DPR) is 35.69%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.